Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Launched by THE NEW YORK PROTON CENTER · Mar 29, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat tumors that have come back in patients who have already received radiation therapy. The focus is on using a special type of radiation called Proton Therapy, which is more targeted than traditional radiation. This means that it can deliver a stronger dose of treatment directly to the tumor while sparing the surrounding healthy tissues. The researchers want to see if this approach can lead to better outcomes for patients with various types of cancer, including brain, head and neck, gastrointestinal, gynecologic, prostate, thoracic, and breast cancers.

To participate in this study, you need to be at least 18 years old and able to give consent for yourself. You should have a recent health check-up and be in fairly good shape, as determined by your doctor. If you have certain other health issues or have had specific types of cancer recently, you might not be eligible. If you join the study, you will receive Proton Therapy and be monitored closely to see how well it works and if there are any side effects. This research could help improve treatment options for patients facing similar challenges in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years
• • Patient provides study specific informed consent prior to study entry.
• • Documented history and physical exam within 90 days prior to registration.
• • ECOG PS 0, 1, or 2 within 90 days prior to registration
• Exclusion Criteria:
• • Non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up.
• • Prior invasive non study malignancy unless disease free for ≥ 3 years
• • Non melanoma skin cancer, low risk prostate cancer, well differentiated thyroid cancers, in situ carcinomas of the oral cavity, cervix, and other organs, and tumors that are not thought to impact the life expectancy of the patient are permissible.
• • History of active connective tissue disorder (i.e., systemic lupus erythematosus, scleroderma), dermatomyositis, xeroderma pigmentosum